FDA Advisers Considering Moderna Covid-19 Booster Shot

- Advertisement -


Vaccine experts are due to meet on Thursday to review the evidence for the third dose of Moderna Shot and recommend it to the FDA.

- Advertisement -

After approving Covid-19 vaccines for adults starting late last year, the FDA has been evaluating applications in recent months to expand the use of the shots to younger ages and the immune protection of people who are vaccinated. To add an extra dose to strengthen, especially against the delta version.

- Advertisement -

FDA authorizes vaccine from Pfizer Inc.

and partner BioNTech SE for Adolescents. The agency has already approved booster doses of the Pfizer-BioNTech vaccine for seniors and adults at high risk of Covid-19 who have already received shots and are at least six months before their first vaccination .

- Advertisement -

It also has authorized boosters from Pfizer-BioNtech and Moderna Vaccine for some people with weakened immune systems.

The FDA is expected to issue its decision on the Moderna booster in the days following the vote. The Centers for Disease Control and Prevention will also support an additional Moderna Dose before it becomes available to the general public.

The panel’s meeting, called the Vaccines and Related Biological Products Advisory Committee, comes as Covid-19 cases drop from high levels of the infectious delta variant in many parts of the country, though they are rising in some states .

Federal health officials are pushing for boosters to maintain immune protection in people who have been previously vaccinated, especially against Delta.

The Biden administration has said that 60 million people will be eligible for Pfizer’s booster shot in the coming weeks.

Adding an additional shot of Moderna would greatly expand the US booster campaign. According to the CDC, more than 69 million people in the US have been fully vaccinated with Moderna’s shot.

Moderna has asked the FDA to authorize a booster that is half the dose of the first two vaccines, and is taken at least six months after the second dose.

In a review posted online ahead of the advisory committee meeting, FDA staff did not take a firm stand on Moderna’s application, and indicated that there may not be enough data to support additional doses.

Staff did not respond to Pfizer’s booster request, which was later granted. FDA staff reviews are part of the normal process before the agency makes a decision to vacate a product.

Advisory panel to meet again on Friday to consider Johnson & Johnson‘s

To review data on second dose application and mixing and matching of vaccines and boosters.

Moderna and J&K’s Covid-19 vaccines are authorized for use in people 18 years of age and older, while the Pfizer-BioNtech vaccine is approved for people 12 years of age and older.

Outside the US, Israel, the UK and the European Medicines Agency have approved the use of the booster, and several countries are rolling out the shots. However, the World Health Organization has encouraged rich countries to delay booster campaigns and send doses to countries with limited supplies.

write to Felicia Schwartz [email protected] . Feather

.

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox